Sidney Kimmel Cancer Center at Jefferson | Strategic Alliance Partners

Two studies focusing on the role of the metabolic profiles of Hodgkin Lymphoma and Diffuse Large B Cell Lymphoma have been accepted for publication in Seminars in Oncology.

Jean Hoffman-Censits, MD, discusses ever-changing bladder cancer field, ongoing combination trials that are showing early promise, and the unmet need of patient selection for novel therapies.

Jean Hoffman-Censits, MD, associate professor of Medical Oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses the future treatment landscape of bladder cancer.

Jean Hoffman-Censits, MD, associate professor of medical oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses immunotherapy in bladder cancer.

Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses the importance of understanding novel agents such as immunotherapeutic across disciplines in the treatment of genitourinary malignancies.

Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses multidisciplinary care for genitourinary malignancies.

Thomas Jefferson University Hospital (Sidney Kimmel Cancer Center at Jefferson) is ranked No. 20 in the Nation in the cancer specialty, according to US News and World Report.

Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses challenges with immunotherapy in genitourinary (GU) malignancies.

A team of Sidney Kimmel Cancer Center (SKCC) investigators from Thomas Jefferson University and Drexel University has recently published a new study in the journal Cancer Research that sheds light on a key mechanism of prostate cancer progression.

Two new studies from the laboratory of Dr. Alex Mazo at the Sidney Kimmel Cancer Center at Thomas Jefferson University, along with collaborators from SKCC, the Vickie and Jack Farber Institute for Neuroscience and other institutions, provide new insights into the structure of chromatin and its implications for cellular differentiation.

Leonard Gomella, MD, professor, chair, Department of Oncology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses ongoing trials of immunotherapy for patients with bladder cancer.

Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses recent updates in the treatment of patients with chronic lymphocytic leukemia (CLL).

Leonard Gomella, MD, professor, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses immunotherapy in bladder cancer.

Adam Dicker, MD, PhD, professor, chair, department of Radiation Oncology Sidney Kimmel Cancer Center, Thomas Jefferson University, discusses the impact of genetic testing for patients with prostate cancer.

Leonard Gomella, MD, professor, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses challenges facing genetic testing for patients with prostate cancer.

Scientists at the Sidney Kimmel Cancer Center at Thomas Jefferson University have developed a non-invasive technique to detect the presence of prostate cancer cells in patients' urine.

Researchers at the Sidney Kimmel Cancer Center at Thomas Jefferson University discover that isomiRs (small non-coding RNA molecules produced in a cell) are powerful enough to classify accurately samples that can belong to 32-different types of cancer.

Scientists from the Sidney Kimmel Cancer Center at Thomas Jefferson University have pinpointed a survival protein for patients suffering from non-Hodgkin's lymphoma.

Scientists at the Sidney Kimmel Cancer Center have been able to validate the contemporary five-tiered Gleason Grade Grouping Using Population-based Data.

A single molecule called DNA-PKcs may drive metastatic processes that turn cancer from a slowly growing, relatively benign disease to a killer.

For some insight on this discussion, OncLive sat down with prostate cancer expert and president-elect of SUO, Leonard G. Gomella, MD.

The 12-month countdown to the adoption of ICD-10 has begun. ICD-10 represents the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (usually referred to as "ICD"), now overseen by the World Health Organization (WHO).

Researchers at Thomas Jefferson University's Kimmel Cancer Center in Philadelphia have developed a model for establishing a comprehensive multidisciplinary geriatric oncology center to avoid the potential overtreatment or undertreatment that elderly patients with cancer may face.

An MRI-guided focused ultrasound approach using heat to alleviate the pain commonly associated with bone metastases has proven to be safe and effective in a multi-center phase III clinical trial, yielding a 64% response rate.

Researchers at Thomas Jefferson University's Kimmel Cancer Center have developed a model for the establishment of a comprehensive multidisciplinary geriatric oncology center to help combat the over or under treatment that elderly oncology patients often face.

An immunotherapy drug for the treatment of prostate cancer, approved in the US in 2010, will soon be available in Europe.

The renaissance in immunology is already affecting treatment paradigms for a variety of gynecologic cancers, and the impact is only likely to expand.

William Kevin Kelly, DO, professor of medical oncology and urology, Thomas Jefferson University, discusses the possibility of preselecting which castration-resistant prostate cancer (CRPC) patients will be sensitive to chemotherapy or hormone therapy.

Russell J. Schilder, MD, director, Gynecologic Medical Oncology, Thomas Jefferson University, Kimmel Cancer Center, discusses PARP inhibitors and their potential role in gynecologic cancers.

Edith Mitchell, MD, FACP, clinical professor, director, Center to Eliminate Cancer Disparities Program Leader, Thomas Jefferson University, discusses an analysis of the VELOUR trial.